NRT Petition Calls On FDA To Greatly Expand Indications, Availability
This article was originally published in The Tan Sheet
Executive Summary
FDA's stated commitment to a public health approach to drug regulation will be put to the test by a petition to expand nicotine replacement therapy indications and availability
You may also be interested in...
Education About NRT Safety Overcomes Smokers’ Cost Barrier – Study
Drug firms could educate consumers about the safety and efficacy of nicotine-replacement therapies to show the products’ value, according to recent research.
Smoking Cessation Growth Opportunities Lay With Employers, Health Care Reform
Many employers still hold a short-sighted view of the cost of smoking cessation therapies, panelists at an American University webinar said Nov. 16.
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication